Compare · NVO vs SYRE
NVO vs SYRE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Spyre Therapeutics Inc. (SYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.82B, about 28.5x SYRE ($6.46B).
- Over the past year, NVO is down 34.2% and SYRE is up 375.3% - SYRE leads by 409.5 points.
- SYRE has been more active in the news (13 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 10 for SYRE).
- Company
- Novo Nordisk A/S
- Spyre Therapeutics Inc.
- Price
- $41.18+6.93%
- $69.72+0.66%
- Market cap
- $183.82B
- $6.46B
- 1M return
- +13.32%
- +52.74%
- 1Y return
- -34.24%
- +375.26%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 5
- 13
- Recent ratings
- 25
- 10
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest SYRE
- SEC Form SCHEDULE 13G filed by Spyre Therapeutics Inc.
- SEC Form 8-K filed by Spyre Therapeutics Inc.
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
- Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
- Raymond James initiated coverage on Spyre Therapeutics with a new price target
- SEC Form 424B5 filed by Spyre Therapeutics Inc.
- Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
- Spyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- Spyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients